BJDX

#4963
Bluejay Diagnostics, Inc. - Common Stock
0.8 5 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.85
0.85
Intervallo Annuale
0.82
7.00
Variazione giornaliera
0.00%
Variazione Mensile
-42.95%
Variazione di 6 mesi
-54.79%
Variazione Annuale
-56.41%
Chiusura Precedente
0.8 5
Open
0.8 5
Minimo
0.8 5
Massimo
0.8 5
Volume
2
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Bluejay Diagnostics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bluejay Diagnostics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bluejay Diagnostics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bluejay Diagnostics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bluejay Diagnostics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bluejay Diagnostics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bluejay Diagnostics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bluejay Diagnostics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bluejay Diagnostics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bluejay Diagnostics, Inc. current report, Q1 FY2026
8-K

Bluejay Diagnostics, Inc. current report, Q3 FY2024

Full document

Bluejay Diagnostics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated August 21, 2024, reports the results of a Special Meeting of Stockholders held by Bluejay Diagnostics, Inc. (BJDX). The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Capital Market.

Key Financial Metrics

This filing is a corporate governance report regarding shareholder voting results. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.

Material Changes and Voting Results

As of the record date (June 24, 2024), there were 563,960 shares outstanding. A quorum was established with 300,978 shares (53.4%) present. Shareholders approved three key proposals:

  • Proposal 1: Amendment to the certificate of incorporation to increase the number of authorized common shares.
    • Votes For: 223,019
    • Votes Against: 32,958
    • Abstain: 45,001
  • Proposal 2: Approval of the issuance of Class C warrants in connection with a securities offering consummated on June 28, 2024.
    • Votes For: 144,962
    • Votes Against: 5,412
    • Abstain: 8,613
  • Proposal 3: Approval of the issuance of Class D warrants in connection with the same June 28, 2024 offering.
    • Votes For: 144,881
    • Votes Against: 5,475
    • Abstain: 8,631

There were 141,991 broker non-voted shares regarding Proposals 2 and 3. Proposal 4 (regarding adjournments) was not voted upon.

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, or specific risk factors. The primary operational update is the company's intent to promptly file the approved amendment to its certificate of incorporation with the Delaware Secretary of State.

Key Facts for Investor Verification

  • Verify the filing of the amended certificate of incorporation with the State of Delaware to confirm the increase in authorized shares.
  • Review the terms of the Class C and Class D warrants approved in connection with the June 28, 2024 offering to understand potential dilution.
  • Note the significant number of abstentions (45,001) on the capital structure amendment (Proposal 1) compared to the warrant approvals.
  • Confirm the total number of authorized shares post-amendment in subsequent filings.

Notizie